Brain metastases. Hormone receptor status. Disease burden.
Drs. Iyengar and Dietrich explain why DESTINY-Breast09 supports an all-comers benefit — and why it’s becoming harder to justify holding back the most effective therapy.
Who Should Receive T-DXd + Pertuzumab in the First Line?
You may also like
Recommended Videos
